Logo image
Back
GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trials
Journal article   Peer reviewed

GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trials

Giulia Carvalhal, Maria Meritxell Roca Mora, Gonzalo Alberto Peralta-Jiménez, Laith Ayasa, Vivian Barrera, Kavita Advani and Jafar Aljazeeri
Sleep & breathing, v 30(5), 279
06 Oct 2026
DOI: https://doi.org/10.1007/s11325-026-03826-5
PMID: 42837024
Featured in Collection :   Drexel's Newest Publications

Abstract

Medicine Medicine & Public Health Otorhinolaryngology Pneumology/Respiratory System Sleep Breathing Physiology and Disorders • Original Article Dentistry Internal Medicine Neurology Pediatrics
Purpose Weight reduction is recommended in all overweight and obese patients with obstructive sleep apnea (OSA). Glucagon-like peptide-1 (GLP-1) receptor agonists-based therapies have demonstrated clinical benefits in reducing weight and could potentially improve OSA outcomes. We aim to analyze the efficacy and safety of GLP-1 receptor agonists-based therapies in patients with moderate-to-severe OSA. Methods We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) that compared GLP-1 receptor agonists-based therapies versus control in adults with moderate-to-severe OSA. We systematically searched electronic databases and registries up to February 10, 2025. Outcomes assessed included apnea–hypopnea index (AHI), body weight, oxygen desaturation index (ODI), minimum oxygen saturation, systolic blood pressure (SBP), diastolic blood pressure (DBP), and adverse events. Results A total of 6 RCTs involving 1,069 participants were included, four evaluating liraglutide and two tirzepatide. Compared with control, GLP-1 receptor agonist-based therapies reduced AHI by − 9.99 events/hour (95% CI, − 16.47 to − 3.50; p  < 0.01; I 2  = 87%) and body weight by − 9.68 kg (95% CI, − 15.84 to − 3.51; p  < 0.01; I 2  = 98%). These therapies also reduced SBP by -4.77 mmHg (95% CI, -7.04 to -2.51; p  < 0.01), and DBP by -1.41 mmHg (95% CI, -2.71 to -0.11; p  = 0.03). No significant differences were observed in ODI or minimum oxygen saturation. GLP-1 receptor agonists-based therapies did not increase the risk of adverse events. Conclusion GLP-1 receptor agonist-based therapies reduced AHI and body weight in the populations studied. Substantial heterogeneity limits interpretation of the pooled effect magnitude. These findings support their potential role within comprehensive OSA management but do not establish them as substitutes for CPAP. Registry International Prospective Register of Systematic Reviews; No.: CRD42024564018; URL: https://www.crd.york.ac.uk/prospero/ . Graphical abstract

Metrics

1 Record Views

Details

Logo image